Search

Your search keyword '"Knop, F K"' showing total 357 results
Start Over Author "Knop, F K"
357 results on '"Knop, F K"'

5. The impact of statins and RAS inhibitors on the association between delayed antidiabetic treatment and the risk of cardiovascular event in patients with a first HbAlc between 48-57 mmol/mol

Author

Falkentoft, A. C., Gerds, T. A., Knop, F. K., Fosbøl, E., Koeber, L., Torp-Pedersen, C., Schou, M., Bruun, N. E., Ruwald, A. C., Falkentoft, A. C., Gerds, T. A., Knop, F. K., Fosbøl, E., Koeber, L., Torp-Pedersen, C., Schou, M., Bruun, N. E., and Ruwald, A. C.

Abstract

Background In addition to lifestyle intervention, guidelines recommend initiation of antidiabetic (AD) treatment within 3 months of diagnosing type 2 diabetes (T2D). Yet, patients with an initial HbA1c level between 48 and 57 mmol/mol may await effects of lifestyle intervention up to 6 months. Omitting initial AD treatment and any lifestyle-induced remission, may affect initiation of statins and renin-angiotensin system inhibitors (RASi) and, thus, cardiovascular risk. Purpose To examine whether omission of initial AD treatment is associated with an increased 5-year risk of first-time major cardiovascular event (MACE: myocardial infarction/stroke/all-cause death) compared with well-controlled patients on AD. Further, whether lower initial use of statins and RASi could explain this excess risk of MACE. Methods We used Danish registers to identify patients with a first-measured HbA1c of 48–57 mmol/mol between 2014 and 2020. We included patients aged 40–80 years without prior atherosclerotic disease that were alive the following 180 days (the index date). At date of index, we divided patients into four groups according to AD treatment and achieved HbA1c (mmol/mol): well-controlled (HbA1c ≤47) on AD; poorly controlled (HbA1c ≥48) on AD; remission (HbA1c ≤47) not on AD; poorly controlled (HbA1c ≥48) not on AD. Based on a Cox-regression model and imputations of treatment values of statins and RASi from two logistic regression models, we examined to what extent the observed standardised 5-year risk of MACE within each group could be reduced if each group had the same probability of treatment initiation with statin and RASi as well-controlled patients on AD. Results We included 14,206 patients (median age 59 [IQR 51–68] years; 52.0% men) with the following distribution according to AD group: well-controlled on AD: 22.3%; poorly controlled on AD: 14.7%; remission not on AD: 38.3%; poorly controlled not on AD: 24.6%. Patients not on

Published
2022

23. Six-day sc GIP infusion increases plasma NEFA without altering the adipose tissue transcriptome, GIPR levels or plasma markers of inflammation in patients with type 1 diabetes

Author

Heimburger, S. M. N., Hoe, B., Nielsen, C. N., Hartmann, B., Holst, J. J., Dela, F., Overgaard, J., Storling, J., Vilsboll, T., Dejgaard, T. F., Pyke, C., Christensen, M. B., Knop, F. K., Heimburger, S. M. N., Hoe, B., Nielsen, C. N., Hartmann, B., Holst, J. J., Dela, F., Overgaard, J., Storling, J., Vilsboll, T., Dejgaard, T. F., Pyke, C., Christensen, M. B., and Knop, F. K.

Published
2021

24. Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity

Author

Bronden, A., Nerild, H. H., Nexoe-Larsen, C. C., Hellmann, P. H., Baekdal, M., Gether, I. M., Gillum, M. P., Hartmann, B., Knudsen, L. B., Jacobsen, L. V., Rehfeld, J. F., Holst, J. J., Vilsboll, T., Sonne, D. P., Knop, F. K., Bronden, A., Nerild, H. H., Nexoe-Larsen, C. C., Hellmann, P. H., Baekdal, M., Gether, I. M., Gillum, M. P., Hartmann, B., Knudsen, L. B., Jacobsen, L. V., Rehfeld, J. F., Holst, J. J., Vilsboll, T., Sonne, D. P., and Knop, F. K.

Published
2021

26. Associations of hypoglycaemia and glycaemic variability with cardiac arrhythmias using a long-term monitoring approach in insulin-treated patients with type 2 diabetes

Author

Andersen, A., Bagger, J. I., Sorensen, S. K., Baldassarre, M. P. A., Pedersen-Bjergaard, U., Forman, J. L., Gislason, G., Lindhardt, T. B., Knop, F. K., Vilsboll, T., Andersen, A., Bagger, J. I., Sorensen, S. K., Baldassarre, M. P. A., Pedersen-Bjergaard, U., Forman, J. L., Gislason, G., Lindhardt, T. B., Knop, F. K., and Vilsboll, T.

Published
2021

39. GIP infusion in patients with type 1 diabetes seems to attenuate post-prandial glucose excursions after prandial insulin over-dose and physical activity

Author

Hoe, B., Heimburger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Hartmann, B., Holst, J. J., Vilsboll, T., Lund, A., Engberg, S., Dejgaard, T. F., Christensen, M. B., Knop, F. K., Hoe, B., Heimburger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Hartmann, B., Holst, J. J., Vilsboll, T., Lund, A., Engberg, S., Dejgaard, T. F., Christensen, M. B., and Knop, F. K.

Published
2020

40. Hepatic steatosis and glucagon resistance develope in parallel resulting in hyperglucagonaemia and hyperaminoacidaemia

Author

Winther-Sorensen, M., Galsgaard, K. D., Santos, A., Pedersen, J., Hassing, A. S., Dall, M., Treebak, J. T., Kjeldsen, S. A. S., Knop, F. K., Werge, M. P., Eriksen, P. L., Vilstrup, H., Gluud, L., Holst, J. J., Albrechtsen, N. J. Wewer, Winther-Sorensen, M., Galsgaard, K. D., Santos, A., Pedersen, J., Hassing, A. S., Dall, M., Treebak, J. T., Kjeldsen, S. A. S., Knop, F. K., Werge, M. P., Eriksen, P. L., Vilstrup, H., Gluud, L., Holst, J. J., and Albrechtsen, N. J. Wewer

Published
2020

41. The impact of acute glycaemic fluctuations on left ventricular systolic function in insulin-treated type 2 diabetes

Author

Andersen, A., Jorgensen, P. G., Bagger, J. I., Baldassarre, M. P. A., Christensen, M., Abelin, K. U., Faber, J., Pedersen-Bjergaard, U., Holst, J. J., Lindhardt, T., Gislason, G., Knop, F. K., Vilsboll, T., Andersen, A., Jorgensen, P. G., Bagger, J. I., Baldassarre, M. P. A., Christensen, M., Abelin, K. U., Faber, J., Pedersen-Bjergaard, U., Holst, J. J., Lindhardt, T., Gislason, G., Knop, F. K., and Vilsboll, T.

Published
2020

42. Counterregulatory responses to hypoglycaemia in totally pancreatectomised patients

Author

Baekdal, M., Lund, A., Baldassare, M. P. A., Rose, K., Egholk, J., Christensen, M. B., Hansen, C. P., Storkholm, J. H., Faber, J., Hartmann, B., Holst, J. J., Villsboll, T., Knop, F. K., Baekdal, M., Lund, A., Baldassare, M. P. A., Rose, K., Egholk, J., Christensen, M. B., Hansen, C. P., Storkholm, J. H., Faber, J., Hartmann, B., Holst, J. J., Villsboll, T., and Knop, F. K.

Published
2020

44. Cardiovascular effects of high-dose glucagon: a randomised clinical trial

Author

Petersen, K. M., Bogevig, S., Riis, T., Andersson, N. A. W., Dalhoff, K. P., Holst, J. J., Knop, F. K., Faber, J., Petersen, T. S., Christensen, M. B., Petersen, K. M., Bogevig, S., Riis, T., Andersson, N. A. W., Dalhoff, K. P., Holst, J. J., Knop, F. K., Faber, J., Petersen, T. S., and Christensen, M. B.

Published
2020

46. Alterations in blood microbiota after colonic cancer surgery

Author

Søby, J. H., Watt, S. K., Vogelsang, R. P., Servant, F., Lelouvier, B., Raskov, H., Knop, F. K., Gogenur, I., Søby, J. H., Watt, S. K., Vogelsang, R. P., Servant, F., Lelouvier, B., Raskov, H., Knop, F. K., and Gogenur, I.

Abstract

Background: Mechanisms contributing to the perioperative stress response remain poorly understood. This study investigated changes in the amount of bacterial DNA in blood and the diversity of blood microbiota in the perioperative period in patients undergoing minimally invasive surgery for colonic cancer in an enhanced recovery after surgery setting.Methods: DNA encoding the bacterial 16S ribosomal RNA gene (16S rDNA) in whole blood obtained the day before surgery, and on postoperative day (POD) 1 and POD 10-14 was amplified and quantified by PCR before sequencing for taxonomic assignment. Richness, evenness and similarity measures were calculated to compare microbiota between days. Differences in relative abundance were analysed using the linear discriminant analysis effect size (LEfSe) algorithm.Results: Thirty patients were included between January and July 2016. The concentration of bacterial 16S rDNA in blood increased between the day before surgery and POD 1 (P = 0.025). Bacterial richness was lower on POD 10-14 than on the day before surgery and POD 1 (bothP <0 center dot 001). LEfSe analysis comparing the day before surgery and POD 10-14 identified changes in the abundance of several bacteria, includingFusobacterium nucleatum, which was relatively enriched on POD 10-14.Conclusion: These findings suggest that the blood of patients with colonic cancer harbours bacterial 16S rDNA, which increases in concentration after surgery.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results